NCT02347917View on ClinicalTrials.gov

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Malignant Pleural MesotheliomaNon-Small Cell Lung Cancer
Interventions
DRUG

BBI608

480 mg orally twice daily (960 mg total daily dose)

DRUG

Pemetrexed

500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).

DRUG

Cisplatin

75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).

Trial Locations (2)

Unknown

National Cancer Center Hospital East, Chiba

National Cancer Center Hospital, Tokyo

All Listed Sponsors
lead

Sumitomo Pharma Co., Ltd.

INDUSTRY

NCT02347917 - A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | Biotech Hunter | Biotech Hunter